Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Health-tech company Sienna Cancer Diagnostics will be expanding its flagship operations to Melbourne’s south-east
  • The expansion will see the company surrounded by high-budget research facilities such as the Monash Technology Precinct
  • The move is officially expected to take place early next year, coinciding with finish dates for the construction of the new laboratory and manufacturing facilities
  • Despite this good news shares slumped 14.3 per cent, sitting at 4.2 cents apiece

Share prices in Sienna Cancer Diagnostics have dropped significantly today, after the company announced an expansion of operations and relocation.

The health-tech research company signed the lease to move home-base operations to Melbourne’s south-east, located across from The Commonwealth Scientific and Industrial Research Organisation and the Monash Technology Precinct.

“This move represents a significant progression for the company,” CEO Matthew Hoskin said.

“We will establish manufacturing for our cutting edge SIEN-NET technology, which is an important milestone,” he added.

SIEN-NET is one of the company’s flagship technologies, able to capture molecular data on multiple targets at once. Even though it’s still in development, this technology could be particularly useful in non-invasive cancer screening processes.

“Additionally, we are preparing for the expansion of our development, manufacturing and commercialisation capabilities, in anticipation of bringing in new products as part of our technology expansion program,” Matthew added.

The company’s new premises holds an office space, research and development laboratories, a warehouse facility and a manufacturing suite. The warehouse will be used as a product line for SIEN-NET when appropriate.

Aussie punters bit the company’s share price hard following news of the new lease however, causing a 14.3 per cent downgrade — sitting at 4.2 cents apiece

Sienna management stated today the move into Melbourne’s south-east is in tune with the city’s district of enterprise and high-tech research facilities.

The new lease is also located nearby the Australian Synchrotron, a major world-class research facility operated by Australia’s Nuclear Science and Technology Organisation (ANSTO).

According to ANSTO, the facility holds the technology capable of radiating one million times brighter than the sun and frequently holds over 4000 research visits a year.

The move is officially expected to take place early next year, coinciding with finish dates for the construction of the new laboratory and manufacturing facilities.

SDX by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - MD and CEO Phillip Lynch

" Race Oncology (ASX:RAC) posts “remarkable” Zantrene results

Race Oncology (RAC) has released further interim results from the Zantrene preclinical heart safety research program.
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion (ASX:ALC) to raise $55m & acquire Silverlink

Alcidion (ALC) has announced plans to raise $55 million and buy patient software specialists, Silverlink PCS Software.
Actinogen Medical (ASX:ACW) - CEO & Managing Director, Dr Steven Gourlay

" Actinogen Medical (ASX:ACW) partners with Oxford University

Actinogen (ACW) has announced a collaboration with Oxford University researchers to investigate Xanamem and a condition called mild autonomous cortisol secretion (MACS).
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) soars on ‘positive’ Rett syndrome trial results

Neuren Pharmaceuticals’ (NEU) shares have soared following positive top-line results from a phase three study on Rett syndrome.